Bank of America started coverage on shares of NextCure (NASDAQ:NXTC) in a research note released on Tuesday morning, Benzinga reports. The firm issued a buy rating and a $25.00 target price on the stock.

A number of other analysts have also commented on NXTC. Piper Jaffray Companies lowered shares of Cypress Semiconductor from an overweight rating to a neutral rating in a research note on Monday, June 3rd. Morgan Stanley lowered shares of Meili from an equal weight rating to an underweight rating and reduced their price target for the stock from $14.00 to $4.20 in a research note on Monday, June 3rd.

Shares of NXTC stock opened at $17.01 on Tuesday. The business has a 50 day moving average of $16.62. NextCure has a 52 week low of $13.86 and a 52 week high of $22.75.

NextCure (NASDAQ:NXTC) last announced its quarterly earnings results on Monday, June 10th. The company reported ($4.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.53) by ($3.93). The firm had revenue of $1.36 million for the quarter. On average, research analysts anticipate that NextCure will post -2.08 EPS for the current fiscal year.

In other NextCure news, Director Stella Xu bought 125,000 shares of the business’s stock in a transaction that occurred on Monday, May 13th. The stock was bought at an average cost of $15.00 per share, for a total transaction of $1,875,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder X L.P. Canaan bought 50,000 shares of the business’s stock in a transaction that occurred on Monday, May 13th. The shares were acquired at an average price of $15.00 per share, with a total value of $750,000.00. The disclosure for this purchase can be found here.

NextCure Company Profile

There is no company description available for NextCure Inc

Read More: Insider Trading – What You Need to Know

Receive News & Ratings for NextCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NextCure and related companies with MarketBeat.com's FREE daily email newsletter.